A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) Meeting Abstract
| Authors: | Abida, W.; Bradley, T. P.; Rezazadeh, A.; Karsh, L. I.; Ross, A.; Saltzstein, D.; Argon, E. K.; Hamlett, A.; Tang, J.; Adib, D. |
| Abstract Title: | A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) |
| Meeting Title: | 2020 Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 6 Suppl. |
| Meeting Dates: | 2020 Feb 13-15 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-02-20 |
| Language: | English |
| ACCESSION: | WOS:000529525900008 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.6_suppl.TPS255 |
| Notes: | Meeting Abstract: TPS255 -- Source: Wos |
